Royalty Net Invested Capital from 2010 to 2025

RPRX Stock  USD 31.59  0.36  1.13%   
Royalty Pharma Net Invested Capital yearly trend continues to be fairly stable with very little volatility. Net Invested Capital will likely drop to about 13.2 B in 2025. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
14.6 B
Current Value
13.2 B
Quarterly Volatility
1.1 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 226 M, Total Revenue of 2.8 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 10.69, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Royalty Pharma Plc over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Royalty Pharma's Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Slightly volatile
   Net Invested Capital   
       Timeline  

Royalty Net Invested Capital Regression Statistics

Arithmetic Mean11,758,474,815
Geometric Mean11,708,906,998
Coefficient Of Variation9.77
Mean Deviation985,183,893
Median11,007,546,000
Standard Deviation1,148,436,122
Sample Variance1318905.5T
Range3.9B
R-Value0.79
Mean Square Error541213.8T
R-Squared0.62
Significance0.0003
Slope189,477,534
Total Sum of Squares19783582.9T

Royalty Net Invested Capital History

202513.2 B
202414.6 B
202312.7 B
202212.7 B
202112.9 B
202010.6 B
201912.3 B

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Net Invested Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Invested Capital14.6 B13.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.